{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:04:48Z","timestamp":1793649888007,"version":"4.5.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The influence of Vitreomacular Interface Abnormalities (VMIA) such as Epiretinal Membrane (ERM) and\/or vitreomacular traction (VMT) on the response of patients with Centre Involving Diabetic Macular Edema (CIDME) to standard of care Anti-VEGF medications is under-researched.<\/jats:p>\n                <jats:p>The aims of this study were:<jats:list list-type=\"order\">\n                  \n                    \n                    <jats:list-item>\n                      <jats:p>To determine the incidence of VMIA at baseline and 12 months amongst treatment naive patients commencing anti-VEGF treatment<\/jats:p>\n                    <\/jats:list-item>\n                  \n                  \n                    \n                    <jats:list-item>\n                      <jats:p>To compare the response to Anti-VEGF medications at 3 monthly intervals for 12 months in a large cohort of patients with and without VMIA on their baseline OCT scan.<\/jats:p>\n                    <\/jats:list-item>\n                  \n                <\/jats:list><\/jats:p>\n                <jats:p>Response was determined in terms of: number of injections, central macular thickness and visual acuity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective case notes review of treatment na\u00efve patients with newly diagnosed CIDME. Included patients had been commenced on intravitreal Anti-VEGF injections (ranibizumab or aflibercept) at a single centre.<\/jats:p>\n                <jats:p>Inclusion criteria were: treatment na\u00efve DME patients with a CMT of 400\u03bc or more receiving anti-VEGF treatment with at least 12 months follow up and in whom macular OCT scans and visual acuity (VA) measurements were available within two weeks of baseline, 3, 6, 9 and 12 months.<\/jats:p>\n                <jats:p>Exclusion criteria included: previous intravitreal therapy, previous vitrectomy, cataract surgery during the follow-up period, concurrent eye conditions affecting vision or CMT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>119 eyes met the inclusion criteria and underwent analysis. Groups were comparable in their baseline demographics. Baseline CMT measurements were comparable at baseline (417\u03bc and 430\u03bc in the No-VMIA and VMIA groups respectively) and improved to approximately 300\u03bc in both groups. From 6 months CMT continued to improve in the no-VMIA while progressively deteriorating in the VMIA group. Change in CMT was statistically different at 12 months between the 2 groups (108\u03bc and 79\u03bc, <jats:italic>p<\/jats:italic>= 0.04). There was a mean of 7 injections after 12 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study has shown a 46% incidence of VMIA amongst patients newly diagnosed with centre involving DME undergoing treatment with anti-VEGF injections. We have also demonstrated a significant difference in CMT and VA response to anti-VEGF treatment in patients with and without VMIA. Initial response was similar between the 2 groups up until 6 months. From 6 to 12 months significant differences in treatment response emerged.<\/jats:p>\n                <jats:p>Differences in clinical response between patients with and without VMIA may help guide further prospective controlled studies and optimise treatment strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-024-06518-6","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T10:01:42Z","timestamp":1716285702000},"page":"3501-3508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema"],"prefix":"10.1007","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6746-0528","authenticated-orcid":false,"given":"Matthew","family":"Maguire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dah","family":"Laidlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"6518_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00417-016-3562-0","volume":"255","author":"Y Wong","year":"2017","unstructured":"Wong Y, Steel DHW, Habib MS et al (2017) Vitreoretinal interface abnormalities in patients treated with ranibizumab for diabetic macular oedema. Graefe's Arch Clin Exp Ophthalmol 255:733\u2013742. https:\/\/doi.org\/10.1007\/s00417-016-3562-0","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"issue":"1","key":"6518_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/jop.2011.0070","volume":"28","author":"P Wu","year":"2012","unstructured":"Wu P, Lai C, Chen C, Kuo C (2012) Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment. J Ocul Pharmacol Ther 28(1):59\u201364. https:\/\/doi.org\/10.1089\/jop.2011.0070","journal-title":"J Ocul Pharmacol Ther"},{"key":"6518_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s10792-013-9884-6","volume":"34","author":"D Yoon","year":"2014","unstructured":"Yoon D, Rusu I, Barbazetto I (2014) Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities. Int Ophthalmol 34:817\u2013823. https:\/\/doi.org\/10.1007\/s10792-013-9884-6","journal-title":"Int Ophthalmol"},{"key":"6518_CR4","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/eye.2008.84","volume":"22","author":"DA Laidlaw","year":"2008","unstructured":"Laidlaw DA (2008) Vitrectomy for diabetic macular oedema. Eye (Lond) 22:1337\u20131341. https:\/\/doi.org\/10.1038\/eye.2008.84","journal-title":"Eye (Lond)"},{"key":"6518_CR5","unstructured":"National Institute for Health and Care Excellence (2013) Ranibizumab for treating diabetic macular oedema, technology appraisal guidance. www.nice.org.uk\/guidance\/ta274"},{"key":"6518_CR6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264.Aflibercept","volume":"372","author":"The Diabetic Retinopathy Clinical Research Network","year":"2015","unstructured":"The Diabetic Retinopathy Clinical Research Network (2015) Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Oedema. N Engl J Med 372:1193\u20131203. https:\/\/doi.org\/10.1056\/NEJMoa1414264.Aflibercept","journal-title":"N Engl J Med"},{"key":"6518_CR7","unstructured":"The Royal Collage of Ophthalmologist (2012) Diabetic Retinopathy Guidelines, 1\u2013147.\u00a0https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/08\/2012-SCI-267-Diabetic-Retinopathy-Guidelines-December-2012.pdf"},{"key":"6518_CR8","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/bjophthalmol-2014-305966","volume":"99","author":"I Akbar Khan","year":"2015","unstructured":"Akbar Khan I, Mohamed MD, Mann SS et al (2015) Prevalence of vitreomacular interface abnormalities on spectral domain optical coherence tomography of patients undergoing macular photocoagulation for centre involving diabetic macular oedema. Br J Ophthalmol 99:1078\u20131081. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305966","journal-title":"Br J Ophthalmol"},{"key":"6518_CR9","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1016\/j.ophtha.2013.07.042","volume":"120","author":"JS Duker","year":"2013","unstructured":"Duker JS, Kaiser PK, Binder S et al (2013) The international vitreomacular traction study group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 120:2611\u20132619. https:\/\/doi.org\/10.1016\/j.ophtha.2013.07.042","journal-title":"Ophthalmology"},{"key":"6518_CR10","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00417-018-4009-6","volume":"256","author":"M Mikhail","year":"2018","unstructured":"Mikhail M, Stewart S, Seow F et al (2018) Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy. Graefe's Arch Clin Exp Ophthalmol 256:1411\u20131418","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"6518_CR11","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1167\/iovs.09-3582","volume":"51","author":"SS Lee","year":"2010","unstructured":"Lee SS, Ghosn C, Yu Z et al (2010) Vitreous VEGF clearance is increased after vitrectomy. Investig Ophthalmol Vis Sci 51:2135\u20132138. https:\/\/doi.org\/10.1167\/iovs.09-3582","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"6518_CR12","first-page":"44","volume":"131","author":"PK Kaiser","year":"2001","unstructured":"Kaiser PK, Riemann CD, Searrs J, Lewis H (2001) Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 131:44\u201349","journal-title":"Ophthalmology"},{"key":"6518_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ajo.2018.12.004","volume":"200","author":"F Hagenau","year":"2019","unstructured":"Hagenau F, Vogt D, Ziada J et al (2019) Vitrectomy for diabetic macular edema: optical coherence tomography criteria and pathology of the vitreomacular interface. Am J Ophthalmol 200:34\u201346. https:\/\/doi.org\/10.1016\/j.ajo.2018.12.004","journal-title":"Am J Ophthalmol"},{"key":"6518_CR14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1001\/archophthalmol.2012.1611.Angiofibrotic","volume":"130","author":"EH Sohn","year":"2014","unstructured":"Sohn EH, He S, Kim LA, Salehi-had H (2014) Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1. Arch Ophthalmol 130:1127\u20131134. https:\/\/doi.org\/10.1001\/archophthalmol.2012.1611.Angiofibrotic","journal-title":"Arch Ophthalmol"},{"key":"6518_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0002675","volume":"3","author":"EJ Kuiper","year":"2008","unstructured":"Kuiper EJ, Van Nieuwenhoven FA, de Smet MD et al (2008) The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. Plos One 3:1\u20137. https:\/\/doi.org\/10.1371\/journal.pone.0002675","journal-title":"PLoS One"},{"key":"6518_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/bjo.76.9.550","volume":"76","author":"R Walshe","year":"1992","unstructured":"Walshe R, Esser P, Wiedemann P, Heimann K (1992) Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal traction. Br J Ophthalmol 76:550\u2013552. https:\/\/doi.org\/10.1136\/bjo.76.9.550","journal-title":"Br J Ophthalmol"},{"key":"6518_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ophtha.2010.08.038","volume":"118","author":"HA El-Sabagh","year":"2011","unstructured":"El-Sabagh HA, Abdelghaffar W, Labib AM et al (2011) Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications. Ophthalmology 118:636\u2013641. https:\/\/doi.org\/10.1016\/j.ophtha.2010.08.038","journal-title":"Ophthalmology"},{"key":"6518_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00417-016-3413-z","volume":"255","author":"MR Romano","year":"2017","unstructured":"Romano MR, Cennamo GG, Amoroso F et al (2017) Intraretinal changes in the presence of epiretinal traction. Graefe\u2019s Arch Clin Exp Ophthalmol 255:31\u201338. https:\/\/doi.org\/10.1007\/s00417-016-3413-z","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"6518_CR19","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0161-6420(88)33004-6","volume":"95","author":"FP Nasrallah","year":"1988","unstructured":"Nasrallah FP, Jalkh AE, Van Coppenolle F et al (1988) The role of the vitreous in diabetic macular edema. Ophthalmology 95:1335\u20131339. https:\/\/doi.org\/10.1016\/S0161-6420(88)33004-6","journal-title":"Ophthalmology"},{"key":"6518_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2016.12.006","volume":"175","author":"A Govetto","year":"2016","unstructured":"Govetto A, Lalane RA, Sarraf D, Figueroa MS (2016) Insights into epiretinal membranes: presence of ectopic inner foveal layers and a new optical coherence tomography staging scheme. Am J Ophthalmol 175:99\u2013113. https:\/\/doi.org\/10.1016\/j.ajo.2016.12.006","journal-title":"Am J Ophthalmol"},{"key":"6518_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jdiacomp.2010.09.006","volume":"25","author":"BT Ozturk","year":"2011","unstructured":"Ozturk BT, Kerimoglu H, Adam M et al (2011) Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema. J Diabetes Complications 25:298\u2013302. https:\/\/doi.org\/10.1016\/j.jdiacomp.2010.09.006","journal-title":"J Diabetes Complications"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06518-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06518-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06518-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T01:02:59Z","timestamp":1732323779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06518-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["6518"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06518-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the Audit review board of Guy\u2019s and St Thomas\u2019 NHS Trust.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"No conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}